{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T01:56:10Z","timestamp":1790560570155,"version":"4.1.0"},"reference-count":91,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T00:00:00Z","timestamp":1790035200000},"content-version":"vor","delay-in-days":264,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Edmond J Safra Accelerating Clinical Trials in Parkinson\u2019s Disease"},{"name":"EJS ACT-PD"},{"name":"Edmond J Safra Foundation"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,9,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>There is an urgent need to speed up clinical trials for potential disease-modifying therapies that slow progression of Parkinson\u2019s disease. The Edmond J Safra Accelerating Clinical Trials in Parkinson\u2019s Disease (EJS ACT-PD) initiative set out to develop a patient-centric and inclusive platform trial using an innovative multi-arm, multi-stage (MAMS) design. We describe the work of the EJS ACT-PD consortium, which included over 90 experts including people with Parkinson\u2019s disease and care partners across six working groups. There were five key challenges: developing an efficient MAMS trial that meets regulatory requirements and is acceptable to people with Parkinson\u2019s; mitigating participant heterogeneity; reducing the risk of simultaneous arm closures; introducing different treatment regimens into a MAMS trial; and maximizing deliverability and accessibility of a MAMS trial. The final design was achieved through an iterative process and critical appraisal of data modelling exploring the impact of participant numbers per arm, trial durations, and endpoints. Every aspect of the design was informed by people with Parkinson\u2019s disease and care partners whose advice ensured acceptability, deliverability, and accessibility. The EJS ACT-PD trial will start with one placebo and three treatment arms, each with 400 participants, with a primary endpoint at 3 years powered to detect a 30% reduction in rate of progression of MDS-Unified Parkinson\u2019s Disease Rating Scale (MDS-UPDRS) Part I and II summed scores. Interim analyses will test for activity using the summed inverse variance weighted MDS-UPDRS Part I, II, and remote Part III scores. Ineffective arms will be closed, allowing participants to be re-randomized. Cost-effectiveness analysis is embedded. Further promising treatments will be added in future arms, subject to additional funding. To maximize accessibility and inclusivity, the trial will allow for study visits to be conducted remotely based on participant preference. National sites were selected to maximize accessibility and inclusive recruitment with core funded staff placed within experienced trial sites to support training and delivery at less experienced centres. By involving people with Parkinson\u2019s and care partners as well as stakeholders with broad scientific expertise, we have developed an inclusive MAMS trial which captures all stages of disease with partial remote delivery and clear design rationales that will significantly speed up the testing of disease-modifying therapies in Parkinson\u2019s disease.<\/jats:p>","DOI":"10.1093\/braincomms\/fcag349","type":"journal-article","created":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T11:08:39Z","timestamp":1789988919000},"source":"Crossref","is-referenced-by-count":0,"title":["The patient-centric development of an inclusive multi-arm multi-stage trial for Parkinson\u2019s disease"],"prefix":"10.1093","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6232-4284","authenticated-orcid":false,"given":"Marie-Louise","family":"Zeissler","sequence":"first","affiliation":[{"name":"Translational and Clinical Research Institute, Newcastle University , Newcastle upon Tyne NE1 7RU ,","place":["UK"]},{"name":"National Institute for Health and Care Research (NIHR) Biomedical Research Centre , Newcastle Upon Tyne NE4 5PL ,","place":["UK"]},{"name":"Faculty of Health, University of Plymouth , Plymouth, PL6 8BT ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Burnell","sequence":"additional","affiliation":[{"name":"Medical Research Council Clinical Trials Unit, University College London , London WC1V 6LJ ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas R","family":"Barber","sequence":"additional","affiliation":[{"name":"National Hospital for Neurology and Neurosurgery , London WC1N 3BG ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6648-3007","authenticated-orcid":false,"given":"Yoav","family":"Ben-Shlomo","sequence":"additional","affiliation":[{"name":"Population Health Sciences, University of Bristol , Bristol BS8 2PS ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline S","family":"Clarke","sequence":"additional","affiliation":[{"name":"Research Department of Primary Care and Population Health, University College London , London NW3 2PF ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sally","family":"Collins","sequence":"additional","affiliation":[{"name":"Translational and Clinical Research Institute, Newcastle University , Newcastle upon Tyne NE1 7RU ,","place":["UK"]},{"name":"National Institute for Health and Care Research (NIHR) Biomedical Research Centre , Newcastle Upon Tyne NE4 5PL ,","place":["UK"]},{"name":"Faculty of Health, University of Plymouth , Plymouth, PL6 8BT ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carl","family":"Counsell","sequence":"additional","affiliation":[{"name":"Institute of Applied Health Sciences, University of Aberdeen , Aberdeen AB25 2ZD ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joy","family":"Duffen","sequence":"additional","affiliation":[{"name":"Cure Parkinson\u2019s , London W1W 6XX ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark J","family":"Edwards","sequence":"additional","affiliation":[{"name":"Institute of Psychiatry, Psychology & Neuroscience (IoPPN), King\u2019s College London, University of London , London SE5 8AB ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Romy","family":"Ellis-Doyle","sequence":"additional","affiliation":[{"name":"Department of Clinical and Movement Neurosciences, UCL Queen Square Institute of Neurology, University College London , London WC1N 3BG ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Gonzalez-Robles","sequence":"additional","affiliation":[{"name":"Department of Clinical and Movement Neurosciences, UCL Queen Square Institute of Neurology, University College London , London WC1N 3BG ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kate","family":"Hockey","sequence":"additional","affiliation":[{"name":"Expert by Experience , London ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Jewell","sequence":"additional","affiliation":[{"name":"Expert by Experience , London ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3419-0354","authenticated-orcid":false,"given":"Michael","family":"Lawton","sequence":"additional","affiliation":[{"name":"Population Health Sciences, University of Bristol , Bristol BS8 2PS ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgia","family":"Mills","sequence":"additional","affiliation":[{"name":"Department of Clinical and Movement Neurosciences, UCL Queen Square Institute of Neurology, University College London , London WC1N 3BG ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Petty","sequence":"additional","affiliation":[{"name":"Faculty of Health, University of Plymouth , Plymouth, PL6 8BT ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dorothy","family":"Salathiel","sequence":"additional","affiliation":[{"name":"Expert by Experience , London ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sue","family":"Whipps","sequence":"additional","affiliation":[{"name":"Expert by Experience , London ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan","family":"Whone","sequence":"additional","affiliation":[{"name":"School of Physiology, Pharmacology & Neuroscience, University of Bristol , Bristol BS8 1TD ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonia","family":"Gandhi","sequence":"additional","affiliation":[{"name":"Department of Clinical and Movement Neurosciences, UCL Queen Square Institute of Neurology, University College London , London WC1N 3BG ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camille B","family":"Carroll","sequence":"additional","affiliation":[{"name":"Translational and Clinical Research Institute, Newcastle University , Newcastle upon Tyne NE1 7RU ,","place":["UK"]},{"name":"National Institute for Health and Care Research (NIHR) Biomedical Research Centre , Newcastle Upon Tyne NE4 5PL ,","place":["UK"]},{"name":"Faculty of Health, University of Plymouth , Plymouth, PL6 8BT ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0752-1813","authenticated-orcid":false,"given":"Thomas","family":"Foltynie","sequence":"additional","affiliation":[{"name":"Department of Clinical and Movement Neurosciences, UCL Queen Square Institute of Neurology, University College London , London WC1N 3BG ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James R","family":"Carpenter","sequence":"additional","affiliation":[{"name":"Medical Research Council Clinical Trials Unit, University College London , London WC1V 6LJ ,","place":["UK"]},{"name":"London School of Hygiene and Tropical Medicine , London WC1E 7HT ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger A","family":"Barker","sequence":"additional","affiliation":[{"name":"Department of Clinical Neurosciences, University of Cambridge , Cambridge CB2 0QQ ,","place":["UK"]},{"name":"Cambridge Stem Cell Institute \u00a0 Cambridge, CB2 0AW ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"the EJS ACT-PD Consortium","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Foltynie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camille B","family":"Carroll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger A","family":"Barker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James R","family":"Carpenter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoav","family":"Ben-Shlomo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark J","family":"Edwards","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan","family":"Whone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carl","family":"Counsell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline S","family":"Clarke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Burnell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kate","family":"Hockey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Jewell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priti","family":"Gros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Barber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anette","family":"Schrag","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rimona S","family":"Weil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline H","family":"Williams-Gray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele T","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lynn","family":"Rochester","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Piccini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henrik","family":"Zetterberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alastair","family":"Noyce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Lawton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashwani","family":"Jha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brook","family":"Huxford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shlomi Haar","family":"Millo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K","family":"Ray Chaudhuri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carroll","family":"Siu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mich\u00e8le","family":"Bartlett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kuhan","family":"Pushparatnam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"van Wamelen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony H V","family":"Schapira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver","family":"Bandmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon R W","family":"Stott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George K","family":"Tofaris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esther","family":"Sammler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather","family":"Mortiboys","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Duty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David T","family":"Dexter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edwin","family":"Jabbari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Mullin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huw","family":"Morris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Breen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Lambert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prasad","family":"Korlipara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monty","family":"Silverdale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kailash","family":"Bhatia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alison J","family":"Yarnall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raj","family":"Khengar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"Collins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fleur","family":"Hudson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Croucher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Bartolomeu-Pires","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veena","family":"Agarwal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Allison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jodie","family":"Forbes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex","family":"Edwards","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheila","family":"Wonnacott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dilan","family":"Athauda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joy","family":"Duffen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonia","family":"Gandhi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily","family":"Henderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jen","family":"Black","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Matthews","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vince","family":"Greaves","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Deeson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurel","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joel","family":"Handley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"Matthews","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"McFarthing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amit","family":"Batla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikul","family":"Bakshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miriam","family":"Parry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natasha","family":"Ratcliffe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheney","family":"Drew","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naveena","family":"Kapur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anaya","family":"Navangul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shafaq","family":"Ali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine","family":"Fletcher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Bale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Gonzalez-Robles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Louise","family":"Zeissler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgia","family":"Mills","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Romy","family":"Ellis-Doyle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sally L","family":"Collins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Petty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,9,22]]},"reference":[{"issue":"10","key":"2026092721215745100_fcag349-B1","doi-asserted-by":"crossref","first-page":"e551","DOI":"10.1016\/S2468-2667(20)30190-0","article-title":"The burden of neurological diseases in Europe: An analysis for the Global Burden of Disease Study 2017","volume":"5","author":"Deuschl","year":"2020","journal-title":"Lancet Public Health."},{"issue":"5","key":"2026092721215745100_fcag349-B2","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/S1474-4422(18)30499-X","article-title":"Global, regional, and national burden of neurological disorders, 1990-2016: A systematic analysis for the Global Burden of Disease Study 2016","volume":"18","author":"GBD 2016 Neurology Collaborators","year":"2019","journal-title":"Lancet Neurol."},{"key":"2026092721215745100_fcag349-B3","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1038\/s41531-020-0117-1","article-title":"Current and projected future economic burden of Parkinson\u2019s disease in the U.S","volume":"6","author":"Yang","year":"2020","journal-title":"NPJ Parkinsons Dis."},{"issue":"s1","key":"2026092721215745100_fcag349-B4","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.3233\/JPD-181474","article-title":"The emerging evidence of the Parkinson pandemic","volume":"8","author":"Dorsey","year":"2018","journal-title":"J Parkinsons Dis."},{"key":"2026092721215745100_fcag349-B5","author":"McFarthing"},{"key":"2026092721215745100_fcag349-B6","unstructured":"Schorken Z, Klapper K, Fiske B. Parkinson\u2019s priority therapeutic clinical pipeline report v2. Michael J Fox Foundation data repository. 2023. Accessed 24 January 2024. https:\/\/zenodo.org\/records\/8070880"},{"issue":"5","key":"2026092721215745100_fcag349-B7","doi-asserted-by":"crossref","first-page":"899","DOI":"10.3233\/JPD-240272","article-title":"Parkinson\u2019s disease drug therapies in the clinical trial pipeline: 2024 update","volume":"14","author":"McFarthing","year":"2024","journal-title":"J Parkinsons Dis."},{"issue":"4","key":"2026092721215745100_fcag349-B8","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1007\/s13311-020-00960-0","article-title":"Overcoming barriers to Parkinson disease trial participation: Increasing diversity and novel designs for recruitment and retention","volume":"17","author":"Vaswani","year":"2020","journal-title":"Neurotherapeutics."},{"issue":"3","key":"2026092721215745100_fcag349-B9","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1111\/ene.12476","article-title":"Clinical evolution of Parkinson\u2019s disease and prognostic factors affecting motor progression: 9-year follow-up study","volume":"22","author":"Reinoso","year":"2015","journal-title":"Eur J Neurol."},{"issue":"1","key":"2026092721215745100_fcag349-B10","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1038\/s41531-022-00287-x","article-title":"The emerging postural instability phenotype in idiopathic Parkinson disease","volume":"8","author":"Skidmore","year":"2022","journal-title":"NPJ Parkinsons Dis."},{"issue":"12","key":"2026092721215745100_fcag349-B11","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1136\/jnnp-2018-318337","article-title":"Developing and validating Parkinson\u2019s disease subtypes and their motor and cognitive progression","volume":"89","author":"Lawton","year":"2018","journal-title":"J Neurol Neurosurg Psychiatry."},{"issue":"1","key":"2026092721215745100_fcag349-B12","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1002\/mds.28312","article-title":"Differences in the presentation and progression of Parkinson\u2019s disease by sex","volume":"36","author":"Iwaki","year":"2021","journal-title":"Mov Disord."},{"issue":"15","key":"2026092721215745100_fcag349-B13","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1212\/WNL.0000000000002461","article-title":"Age at onset and Parkinson disease phenotype","volume":"86","author":"Pagano","year":"2016","journal-title":"Neurology"},{"issue":"8","key":"2026092721215745100_fcag349-B14","doi-asserted-by":"crossref","first-page":"2490","DOI":"10.1093\/brain\/awaa181","article-title":"Natural history of motor symptoms in Parkinson\u2019s disease and the long-duration response to levodopa","volume":"143","author":"Cilia","year":"2020","journal-title":"Brain."},{"issue":"5","key":"2026092721215745100_fcag349-B15","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1002\/mds.27361","article-title":"Longitudinal change of clinical and biological measures in early Parkinson\u2019s disease: Parkinson\u2019s progression markers initiative cohort","volume":"33","author":"Simuni","year":"2018","journal-title":"Mov Disord."},{"issue":"1","key":"2026092721215745100_fcag349-B16","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1002\/mdc3.12553","article-title":"Progression of MDS-UPDRS scores over five years in DE Novo Parkinson disease from the Parkinson\u2019s progression markers initiative cohort","volume":"5","author":"Holden","year":"2018","journal-title":"Mov Disord Clin Pract."},{"issue":"7","key":"2026092721215745100_fcag349-B17","doi-asserted-by":"crossref","first-page":"2717","DOI":"10.1093\/brain\/awad063","article-title":"Towards a multi-arm multi-stage platform trial of disease modifying approaches in Parkinson\u2019s disease","volume":"146","author":"Foltynie","year":"2023","journal-title":"Brain."},{"issue":"5","key":"2026092721215745100_fcag349-B18","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1177\/1740774517725697","article-title":"Testing many treatments within a single protocol over 10 years at MRC clinical trials unit at UCL: Multi-arm, multi-stage platform, umbrella and basket protocols","volume":"14","author":"Parmar","year":"2017","journal-title":"Clin Trials"},{"issue":"7","key":"2026092721215745100_fcag349-B19","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2022-064173","article-title":"Motor Neuron Disease Systematic Multi-Arm Adaptive Randomised Trial (MND-SMART): A multi-arm, multi-stage, adaptive, platform, phase III randomised, double-blind, placebo-controlled trial of repurposed drugs in motor neuron disease","volume":"12","author":"Wong","year":"2022","journal-title":"BMJ Open"},{"key":"2026092721215745100_fcag349-B20","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1186\/1745-6215-13-168","article-title":"Flexible trial design in practice - stopping arms for lack-of-benefit and adding research arms mid-trial in STAMPEDE: A multi-arm multi-stage randomized controlled trial","volume":"13","author":"Sydes","year":"2012","journal-title":"Trials"},{"issue":"Suppl 2","key":"2026092721215745100_fcag349-B21","doi-asserted-by":"crossref","first-page":"S250","DOI":"10.1093\/infdis\/jis041","article-title":"Innovative trial designs are practical solutions for improving the treatment of tuberculosis","volume":"205","author":"Phillips","year":"2012","journal-title":"J Infect Dis."},{"issue":"18","key":"2026092721215745100_fcag349-B22","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1212\/WNL.0000000000200604","article-title":"Designing multi-arm multistage adaptive trials for neuroprotection in progressive multiple sclerosis","volume":"98","author":"Li","year":"2022","journal-title":"Neurology"},{"issue":"3","key":"2026092721215745100_fcag349-B23","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2021-055615","article-title":"Uptake of the multi-arm multi-stage (MAMS) adaptive platform approach: A trial-registry review of late-phase randomised clinical trials","volume":"12","author":"Noor","year":"2022","journal-title":"BMJ Open"},{"issue":"2","key":"2026092721215745100_fcag349-B24","doi-asserted-by":"crossref","first-page":"413","DOI":"10.3233\/JPD-191856","article-title":"Is it possible to conduct a multi-arm multi-stage platform trial in Parkinson\u2019s disease: Lessons learned from other neurodegenerative disorders and cancer","volume":"10","author":"Zeissler","year":"2020","journal-title":"J Parkinsons Dis."},{"issue":"7","key":"2026092721215745100_fcag349-B25","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1002\/mds.30190","article-title":"Treatment selection and prioritization for the EJS ACT-PD MAMS trial platform","volume":"40","author":"Gonzalez-Robles","year":"2025","journal-title":"Mov Disord."},{"issue":"6","key":"2026092721215745100_fcag349-B26","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.3233\/JPD-230051","article-title":"Outcome measures for disease-modifying trials in Parkinson\u2019s disease: Consensus paper by the EJS ACT-PD multi-arm multi-stage trial initiative","volume":"13","author":"Gonzalez-Robles","year":"2023","journal-title":"J Parkinsons Dis."},{"issue":"2","key":"2026092721215745100_fcag349-B27","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1002\/mds.29691","article-title":"Embedding patient input in outcome measures for long-term disease-modifying Parkinson disease trials","volume":"39","author":"Gonzalez-Robles","year":"2024","journal-title":"Mov Disord."},{"issue":"4","key":"2026092721215745100_fcag349-B28","doi-asserted-by":"crossref","first-page":"809","DOI":"10.3233\/JPD-230444","article-title":"Patient and public involvement and engagement in the development of a platform clinical trial for Parkinson\u2019s disease: An evaluation protocol","volume":"14","author":"Zeissler","year":"2024","journal-title":"J Parkinsons Dis."},{"issue":"8","key":"2026092721215745100_fcag349-B29","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.3233\/JPD-230109","article-title":"An international multi-stakeholder Delphi survey study on the design of disease modifying Parkinson\u2019s disease trials","volume":"13","author":"Zeissler","year":"2023","journal-title":"J Parkinsons Dis."},{"issue":"Pt 3","key":"2026092721215745100_fcag349-B30","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1093\/brain\/awh067","article-title":"The cognitive ability of an incident cohort of Parkinson\u2019s patients in the UK. The CamPaIGN study","volume":"127","author":"Foltynie","year":"2004","journal-title":"Brain."},{"issue":"4","key":"2026092721215745100_fcag349-B31","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1212\/WNL.0000000000000066","article-title":"Characterizing mild cognitive impairment in incident Parkinson disease: The ICICLE-PD study","volume":"82","author":"Yarnall","year":"2014","journal-title":"Neurology"},{"issue":"4","key":"2026092721215745100_fcag349-B32","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/j.pneurobio.2011.09.005","article-title":"The Parkinson progression marker initiative (PPMI)","volume":"95","author":"Marek","year":"2011","journal-title":"Prog Neurobiol."},{"issue":"1","key":"2026092721215745100_fcag349-B33","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.parkreldis.2013.09.025","article-title":"The influence of age and gender on motor and non-motor features of early Parkinson\u2019s disease: Initial findings from the Oxford Parkinson Disease Center (OPDC) discovery cohort","volume":"20","author":"Szewczyk-Krolikowski","year":"2014","journal-title":"Parkinsonism Relat Disord."},{"issue":"4","key":"2026092721215745100_fcag349-B34","doi-asserted-by":"crossref","first-page":"947","DOI":"10.3233\/JPD-150662","article-title":"Tracking Parkinson\u2019s: Study design and baseline patient data","volume":"5","author":"Malek","year":"2015","journal-title":"J Parkinsons Dis."},{"issue":"9","key":"2026092721215745100_fcag349-B35","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1136\/jnnp-2015-312581","article-title":"Comparative epidemiology of incident Parkinson\u2019s disease in Cambridgeshire, UK","volume":"87","author":"Evans","year":"2016","journal-title":"J Neurol Neurosurg Psychiatry."},{"issue":"5","key":"2026092721215745100_fcag349-B36","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1212\/01.wnl.0000201252.57661.e1","article-title":"A randomized, double-blind, futility clinical trial of creatine and minocycline in early Parkinson disease","volume":"66","author":"NINDS NET-PD Investigators","year":"2006","journal-title":"Neurology"},{"issue":"1","key":"2026092721215745100_fcag349-B37","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1212\/01.wnl.0000250355.28474.8e","article-title":"A randomized clinical trial of coenzyme Q10 and GPI-1485 in early Parkinson disease","volume":"68","author":"NINDS NET-PD Investigators","year":"2007","journal-title":"Neurology"},{"issue":"6","key":"2026092721215745100_fcag349-B38","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1001\/jama.2015.120","article-title":"Effect of creatine monohydrate on clinical progression in patients with Parkinson disease: A randomized clinical trial","volume":"313","author":"Writing Group for the NINDS Exploratory Trials in Parkinson Disease (NET-PD) Investigators","year":"2015","journal-title":"JAMA"},{"issue":"2","key":"2026092721215745100_fcag349-B39","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1001\/jamaneurol.2013.5528","article-title":"Inosine to increase serum and cerebrospinal fluid urate in Parkinson disease: A randomized clinical trial","volume":"71","author":"Parkinson Study Group SURE-PD Investigators","year":"2014","journal-title":"JAMA Neurol."},{"issue":"9","key":"2026092721215745100_fcag349-B40","doi-asserted-by":"crossref","first-page":"591","DOI":"10.7326\/M19-2534","article-title":"Isradipine versus placebo in early Parkinson disease: A randomized trial","volume":"172","author":"Parkinson Study Group STEADY-PD III Investigators","year":"2020","journal-title":"Ann Intern Med."},{"issue":"10","key":"2026092721215745100_fcag349-B41","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1001\/jama.2021.10207","article-title":"Effect of urate-elevating inosine on early Parkinson disease progression: The SURE-PD3 randomized clinical trial","volume":"326","author":"Parkinson Study Group SURE-PD3 Investigators","year":"2021","journal-title":"JAMA"},{"key":"2026092721215745100_fcag349-B42","author":"Critical Path for Parkinson\u2019s"},{"issue":"10","key":"2026092721215745100_fcag349-B43","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1002\/mds.25122","article-title":"Calibration of unified Parkinson\u2019s disease rating scale scores to Movement Disorder Society-unified Parkinson\u2019s disease rating scale scores: Calibration of UPDRS scores to MDS-UPDRS scores","volume":"27","author":"Goetz","year":"2012","journal-title":"Mov Disord."},{"issue":"3","key":"2026092721215745100_fcag349-B44","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1056\/NEJM199301213280305","article-title":"Effects of tocopherol and deprenyl on the progression of disability in early Parkinson\u2019s disease","volume":"328","author":"Parkinson Study Group","year":"1993","journal-title":"N Engl J Med."},{"key":"2026092721215745100_fcag349-B45","author":"Burnell"},{"issue":"10","key":"2026092721215745100_fcag349-B46","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1136\/jnnp.2011.240366","article-title":"The natural history of treated Parkinson\u2019s disease in an incident, community based cohort","volume":"82","author":"Evans","year":"2011","journal-title":"J Neurol Neurosurg Psychiatry."},{"issue":"4","key":"2026092721215745100_fcag349-B47","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1212\/WNL.35.4.522","article-title":"The heterogeneity of Parkinson\u2019s disease: Clinical and prognostic implications","volume":"35","author":"Zetusky","year":"1985","journal-title":"Neurology"},{"key":"2026092721215745100_fcag349-B48","author":"EMA"},{"issue":"2","key":"2026092721215745100_fcag349-B49","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1002\/mds.29279","article-title":"It is as it was: MDS-UPDRS part III scores cannot be combined with other parts to give a valid sum","volume":"38","author":"Goetz","year":"2023","journal-title":"Mov Disord."},{"issue":"7","key":"2026092721215745100_fcag349-B50","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1002\/mds.29417","article-title":"Summing MDS-UPDRS parts 1 + 2 (non-motor and motor experience of daily living): The patient\u2019s voice","volume":"38","author":"Zou","year":"2023","journal-title":"Mov Disord."},{"key":"2026092721215745100_fcag349-B51","doi-asserted-by":"publisher","author":"Burnell","DOI":"10.64898\/2026.03.27.26349548"},{"issue":"1","key":"2026092721215745100_fcag349-B52","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/1745-6215-10-39","article-title":"Issues in applying multi-arm multi-stage methodology to a clinical trial in prostate cancer: The MRC STAMPEDE trial","volume":"10","author":"Sydes","year":"2009","journal-title":"Trials"},{"key":"2026092721215745100_fcag349-B53","author":"Food and Drug Administration U.S"},{"key":"2026092721215745100_fcag349-B54","doi-asserted-by":"crossref","DOI":"10.1016\/j.cct.2021.106515","article-title":"Eligibility criteria and clinical trials: An FDA perspective","volume":"109","author":"Duggal","year":"2021","journal-title":"Contemp Clin Trials."},{"issue":"1","key":"2026092721215745100_fcag349-B55","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1186\/s13063-020-04613-7","article-title":"Developing a roadmap to improve trial delivery for under-served groups: Results from a UK multi-stakeholder process","volume":"21","author":"Witham","year":"2020","journal-title":"Trials"},{"issue":"8","key":"2026092721215745100_fcag349-B56","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1136\/jnnp.2006.103788","article-title":"Gender differences in Parkinson\u2019s disease","volume":"78","author":"Haaxma","year":"2007","journal-title":"J Neurol Neurosurg Psychiatry."},{"issue":"1","key":"2026092721215745100_fcag349-B57","doi-asserted-by":"crossref","first-page":"437","DOI":"10.3233\/JPD-212860","article-title":"Longitudinal change and progression indicators using the movement disorder society-Unified Parkinson\u2019s disease Rating Scale in two independent cohorts with early Parkinson\u2019s disease","volume":"12","author":"Bartl","year":"2022","journal-title":"J Parkinsons Dis."},{"issue":"4","key":"2026092721215745100_fcag349-B58","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1002\/mdc3.12476","article-title":"Differences in MDS-UPDRS scores based on Hoehn and Yahr stage and disease duration","volume":"4","author":"Skorvanek","year":"2017","journal-title":"Mov Disord Clin Pract."},{"issue":"10","key":"2026092721215745100_fcag349-B59","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1002\/mds.27790","article-title":"Measuring Parkinson\u2019s disease over time: The real-world within-subject reliability of the MDS-UPDRS","volume":"34","author":"Evers","year":"2019","journal-title":"Mov Disord."},{"issue":"15","key":"2026092721215745100_fcag349-B60","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1002\/mds.22340","article-title":"Movement Disorder Society-sponsored revision of the Unified Parkinson\u2019s Disease Rating Scale (MDS-UPDRS): Scale presentation and clinimetric testing results","volume":"23","author":"Goetz","year":"2008","journal-title":"Mov Disord."},{"issue":"1","key":"2026092721215745100_fcag349-B61","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1007\/s00415-012-6624-1","article-title":"Expanded and independent validation of the Movement Disorder Society-Unified Parkinson\u2019s Disease Rating Scale (MDS-UPDRS)","volume":"260","author":"Martinez-Martin","year":"2013","journal-title":"J Neurol."},{"issue":"5","key":"2026092721215745100_fcag349-B62","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1002\/sim.1366","article-title":"Comparison of stratification and adaptive methods for treatment allocation in an acute stroke clinical trial","volume":"22","author":"Weir","year":"2003","journal-title":"Stat Med."},{"issue":"10","key":"2026092721215745100_fcag349-B63","doi-asserted-by":"crossref","first-page":"e894","DOI":"10.1212\/WNL.0000000000006134","article-title":"REM behavior disorder predicts motor progression and cognitive decline in Parkinson disease","volume":"91","author":"Pagano","year":"2018","journal-title":"Neurology"},{"key":"2026092721215745100_fcag349-B64","doi-asserted-by":"crossref","DOI":"10.3389\/fnagi.2023.1109914","article-title":"Association between diabetes mellitus, prediabetes and risk, disease progression of Parkinson\u2019s disease: A systematic review and meta-analysis","volume":"15","author":"Zhong","year":"2023","journal-title":"Front Aging Neurosci."},{"issue":"11","key":"2026092721215745100_fcag349-B65","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1016\/S1474-4422(17)30328-9","article-title":"Large-scale identification of clinical and genetic predictors of motor progression in patients with newly diagnosed Parkinson\u2019s disease: A longitudinal cohort study and validation","volume":"16","author":"Latourelle","year":"2017","journal-title":"Lancet Neurol."},{"issue":"11","key":"2026092721215745100_fcag349-B66","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.1007\/s10072-018-3522-z","article-title":"Disease progression in Parkinson subtypes: The PPMI dataset","volume":"39","author":"Aleksovski","year":"2018","journal-title":"Neurol Sci."},{"issue":"13","key":"2026092721215745100_fcag349-B67","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1002\/mds.21537","article-title":"Prognostic factors for the progression of Parkinson\u2019s disease: A systematic review","volume":"22","author":"Post B, Merkus MP, de Haan RJ, Speelman JD, CARPA Study Group","year":"2007","journal-title":"Mov Disord."},{"issue":"5","key":"2026092721215745100_fcag349-B68","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1177\/15459683231172752","article-title":"Does exercise attenuate disease progression in people with Parkinson\u2019s disease? A systematic review with meta-analyses","volume":"37","author":"Li","year":"2023","journal-title":"Neurorehabil Neural Repair."},{"key":"2026092721215745100_fcag349-B69","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1007\/978-3-662-44519-8_8","article-title":"Great expectations: The placebo effect in Parkinson\u2019s disease","volume":"225","author":"Lidstone","year":"2014","journal-title":"Handb Exp Pharmacol."},{"issue":"9","key":"2026092721215745100_fcag349-B70","doi-asserted-by":"crossref","first-page":"1716","DOI":"10.1002\/mds.29514","article-title":"Longitudinal meta-analysis of historical Parkinson\u2019s disease trials to inform future trial design","volume":"38","author":"Arshad","year":"2023","journal-title":"Mov Disord."},{"key":"2026092721215745100_fcag349-B71","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/bs.irn.2018.07.014","article-title":"Are blue pills better than green? How treatment features modulate placebo effects","volume":"139","author":"Meissner","year":"2018","journal-title":"Int Rev Neurobiol."},{"issue":"11","key":"2026092721215745100_fcag349-B72","doi-asserted-by":"crossref","first-page":"2682","DOI":"10.1038\/d41591-023-00080-0","article-title":"The role of placebo control in clinical trials for neurodegenerative diseases","volume":"29","author":"Mehta","year":"2023","journal-title":"Nat Med."},{"issue":"8","key":"2026092721215745100_fcag349-B73","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.1002\/mds.28630","article-title":"Expectations of benefit in a trial of a candidate disease-modifying treatment for Parkinson disease","volume":"36","author":"Mestre","year":"2021","journal-title":"Mov Disord."},{"key":"2026092721215745100_fcag349-B74","doi-asserted-by":"publisher","author":"Petty","DOI":"10.64898\/2026.06.04.26354792"},{"issue":"1","key":"2026092721215745100_fcag349-B75","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1007\/s11136-015-1071-y","article-title":"Development and validation of a carers quality-of-life questionnaire for parkinsonism (PQoL Carers)","volume":"25","author":"Pillas","year":"2016","journal-title":"Qual Life Res."},{"issue":"5","key":"2026092721215745100_fcag349-B76","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.3233\/JPD-212987","article-title":"Enhancing trial delivery in Parkinson\u2019s disease: Qualitative insights from PD STAT","volume":"12","author":"Kehagia","year":"2022","journal-title":"J Parkinsons Dis."},{"issue":"6","key":"2026092721215745100_fcag349-B77","doi-asserted-by":"crossref","first-page":"958","DOI":"10.3390\/medicina60060958","article-title":"Neurological examination via telemedicine: An updated review focusing on movement disorders","volume":"60","author":"Angelopoulou","year":"2024","journal-title":"Medicina (Kaunas)"},{"issue":"3","key":"2026092721215745100_fcag349-B78","doi-asserted-by":"crossref","first-page":"905","DOI":"10.3233\/JPD-212593","article-title":"A call to action: Promoting diversity, equity, and inclusion in Parkinson\u2019s research and care","volume":"11","author":"Siddiqi","year":"2021","journal-title":"J Parkinsons Dis."},{"key":"2026092721215745100_fcag349-B79","doi-asserted-by":"crossref","first-page":"37","DOI":"10.3310\/nihropenres.13434.2","article-title":"Enablers and barriers to engaging under-served groups in research: Survey of the United Kingdom research professional\u2019s views","volume":"3","author":"Coe","year":"2023","journal-title":"NIHR Open Res."},{"key":"2026092721215745100_fcag349-B80","author":"Ministry of Housing, Communities and Local Government"},{"key":"2026092721215745100_fcag349-B81","author":"Scottish Government"},{"key":"2026092721215745100_fcag349-B82","author":"StatsWales"},{"key":"2026092721215745100_fcag349-B83","author":"Northern Ireland Statistics and Research Agency"},{"issue":"5","key":"2026092721215745100_fcag349-B84","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1002\/mds.22432","article-title":"Neuroprotection trials in Parkinson\u2019s disease: Systematic review","volume":"24","author":"Hart","year":"2009","journal-title":"Mov Disord."},{"key":"2026092721215745100_fcag349-B85","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1186\/s12883-016-0606-3","article-title":"A review of clinical trial designs used to detect a disease-modifying effect of drug therapy in Alzheimer\u2019s disease and Parkinson\u2019s disease","volume":"16","author":"McGhee","year":"2016","journal-title":"BMC Neurol."},{"issue":"1","key":"2026092721215745100_fcag349-B86","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1177\/1877718X241291986","article-title":"Improving recruitment and retention of people with Parkinson\u2019s disease to clinical studies: A scoping review","volume":"15","author":"Petty","year":"2025","journal-title":"J Parkinsons Dis."},{"issue":"6","key":"2026092721215745100_fcag349-B87","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1007\/s43441-020-00179-3","article-title":"Evaluation of the content validity and cross-cultural validity of the Study Participant Feedback Questionnaire (SPFQ)","volume":"54","author":"Greene","year":"2020","journal-title":"Ther Innov Regul Sci."},{"issue":"2","key":"2026092721215745100_fcag349-B88","doi-asserted-by":"crossref","first-page":"e243","DOI":"10.7861\/fhj.2021-0083","article-title":"Making trials part of good clinical care: Lessons from the RECOVERY trial","volume":"8","author":"Pessoa-Amorim","year":"2021","journal-title":"Future Healthc J."},{"issue":"11","key":"2026092721215745100_fcag349-B89","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1016\/S1474-4422(24)00326-0","article-title":"Safety and efficacy of memantine and trazodone versus placebo for motor neuron disease (MND SMART): Stage two interim analysis from the first cycle of a phase 3, multiarm, multistage, randomised, adaptive platform trial","volume":"23","author":"Pal","year":"2024","journal-title":"Lancet Neurol."},{"issue":"9","key":"2026092721215745100_fcag349-B90","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1002\/mds.29899","article-title":"Advantages and challenges of platform trials for disease modifying therapies in Parkinson\u2019s disease","volume":"39","author":"Fabbri","year":"2024","journal-title":"Mov Disord."},{"key":"2026092721215745100_fcag349-B91","author":"CureParkinson\u2019s"}],"container-title":["Brain Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/braincomms\/advance-article-pdf\/doi\/10.1093\/braincomms\/fcag349\/71301830\/fcag349.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/braincomms\/article-pdf\/8\/5\/fcag349\/71301830\/fcag349.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/braincomms\/article-pdf\/8\/5\/fcag349\/71301830\/fcag349.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T01:22:12Z","timestamp":1790558532000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/braincomms\/article\/doi\/10.1093\/braincomms\/fcag349\/8826396"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":91,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,9,1]]}},"URL":"https:\/\/doi.org\/10.1093\/braincomms\/fcag349","relation":{},"ISSN":["2632-1297"],"issn-type":[{"value":"2632-1297","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026]]},"published":{"date-parts":[[2026]]},"article-number":"fcag349"}}